Elastin-like recombinamer-based devices releasing Kv1.3 blockers for the prevention of intimal hyperplasia: An in vitro and in vivo study
Source abstract
Abstract
Coronary artery disease (CAD) is the most common cardiovascular disorder. Vascular surgery strategies for coronary revascularization (either percutaneous or open) show a high rate of failure because of restenosis of the vessel, due to phenotypic switch of vascular smooth muscle cells (VSMCs) leading to proliferation and migration. We have previously reported that the inhibition of Kv1.3 channel function with selective blockers represents an effective strategy for the prevention of restenosis in human vessels used for coronary angioplasty procedures. However, delivery systems for controlled release of these drugs have not been investigated. Here we tested the efficacy of several formulations of elastin like recombinamers (ELRs) hydrogels to deliver the Kv1.3 blocker PAP-1 in various restenosis models. The dose and time course of PAP-1 release from ELRs click hydrogels was able to inhibit human VSMC proliferation in vitro as well as remodeling of human vessels in organ culture and restenosis in in vivo models. We conclude that this combination of active compound and advanced delivery method could improve the outcomes of vascular surgery in patients. STATEMENT OF SIGNIFICANCE: Vascular surgery strategies for coronary revascularization show a high rate of failure, because of occlusion (restenosis) of the vessel, due to vascular smooth muscle cells proliferation and migration. We have previously reported that blockers of Kv1.3 channels represent an effective anti-restenosis therapy, but delivery systems for their controlled release have not being explored. Here we tested the efficacy of several formulations of elastin like recombinamers (ELRs) hydrogels to deliver the Kv1.3 blocker PAP-1 in various restenosis models, both in vivo and in vitro, and also in human vessels. We demonstrated that combination of active compound and advanced delivery method could improve the outcomes of vascular surgery in patients.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Connective tissue disorders research · Electrospun Nanofibers in Biomedical Applications · Aortic Disease and Treatment Approaches
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. M. Nichols, N. Townsend, P. Scarborough, M. Rayner, Cardiovascular disease in Europe: epidemiological update, Eur Hear. J.34 (2013) 3028–3034.10.1093/eurheartj/eht356 ↗
2. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease10.1146/annurev-physiol-012110-142315 ↗
3. Stent thrombosis and restenosis: what have we learned and where are we going? the Andreas Grüntzig Lecture ESC 201410.1093/eurheartj/ehv511 ↗
4. Eagle · J. Am. Coll. Cardiol. · 2004 · 44 · e21310.1016/j.jacc.2004.07.021 ↗
5. Role of smooth muscle cells in coronary artery bypass grafting failure10.1093/cvr/cvy021 ↗
6. Vein graft failure10.1016/j.jvs.2013.08.019 ↗
7. Perivascular medical devices and drug delivery systems: making the right choices10.1016/j.biomaterials.2017.02.028 ↗
8. Characterization of ion channels involved in the proliferative response of femoral artery smooth muscle cells10.1161/ATVBAHA.110.205187 ↗
9. Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers10.1093/cvr/cvq305 ↗
10. Kv1.3 channels modulate human vascular smooth muscle cells proliferation independently of mTOR signaling pathway10.1007/s00424-014-1607-y ↗
11. Myocardin-dependent Kv1.5 channel expression prevents phenotypic modulation of human vessels in organ culture10.1161/ATVBAHA.119.313492 ↗
12. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases10.1124/mol.105.015669 ↗
13. A DNA vaccine delivery platform based on elastin-like recombinamer nanosystems for rift valley fever virus10.1021/acs.molpharmaceut.0c00054 ↗
14. Recombinant technology in the development of materials and systems for soft-tissue repair10.1002/adhm.201500152 ↗
15. Elastin-like recombinamers as smart drug delivery systems10.2174/1389450117666160201114617 ↗
16. “Recombinamers” as advanced materials for the post-oil age10.1016/j.polymer.2009.08.032 ↗
17. Elastin-like recombinamer catalyst-free click gels: characterization of poroelastic and intrinsic viscoelastic properties10.1016/j.actbio.2014.02.006 ↗
18. Elastin-like recombinamer-covered stents: towards a fully biocompatible and non-thrombogenic device for cardiovascular diseases10.1016/j.actbio.2014.10.029 ↗
19. Layer-by-layer biofabrication of coronary covered stents with clickable elastin-like recombinamers10.1016/j.eurpolymj.2019.109334 ↗
20. Silk-ELR co-recombinamer covered stents obtained by electrospinning10.1093/rb/rby022 ↗
21. Novel crosslinking methods to design hydrogels10.1016/S0169-409X(01)00240-X ↗
22. Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy10.1016/j.jconrel.2016.02.040 ↗
23. An injectable elastin-based gene delivery platform for dose-dependent modulation of angiogenesis and inflammation for critical limb ischemia10.1016/j.biomaterials.2015.06.037 ↗
24. Tethering QK peptide to enhance angiogenesis in elastin-like recombinamer (ELR) hydrogels10.1007/s10856-019-6232-z ↗
25. Analysis of Fickian and non-Fickian drug release from polymers
26. Contribution of Kv channels to phenotypic remodeling of human uterine artery smooth muscle cells10.1161/01.RES.0000194322.91255.13 ↗
27. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow10.1161/01.ATV.17.10.2238 ↗
28. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils10.1161/01.ATV.20.2.335 ↗
29. An elastin-like recombinamer-based bioactive hydrogel embedded with mesenchymal stromal cells as an injectable scaffold for osteochondral repair10.1093/rb/rbz023 ↗
30. A comparison between the use of dynamic mechanical analysis and oscillatory shear rheometry for the characterisation of hydrogels10.1016/S0378-5173(02)00328-9 ↗
31. G.M. Ravanagh, S.B. Ross-Murphy, Rheological Characterisation of Polymer Gels, 1998.10.1016/S0079-6700(97)00047-6 ↗
32. Tschoegl · 1989
33. Elastin-like recombinamer-covered stents: towards a fully biocompatible and non-thrombogenic device for cardiovascular diseases10.1016/j.actbio.2014.10.029 ↗
34. Drug-eluting coronary stents: insights from preclinical and pathology studies10.1038/s41569-019-0234-x ↗
35. In-stent stenosis: Pathology and implications for the development of drug eluting stents10.1136/heart.89.2.218 ↗
36. Ion channels in innate and adaptive immunity10.1146/annurev-immunol-032414-112212 ↗
37. Kv1.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count10.1113/jphysiol.2010.188136 ↗
38. Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages10.1074/jbc.M304388200 ↗
39. Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat10.3109/00498254.2010.532886 ↗
40. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques10.3181/0705-RM-148 ↗
41. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo10.1002/glia.23457 ↗
42. Effect of the Kv1.3 voltage-gated potassium channel blocker PAP-1 on the initiation and progress of atherosclerosis in a rat model10.1007/s00380-013-0462-7 ↗
43. PAP-1 ameliorates DSS-induced colitis with involvement of NLRP3 inflammasome pathway10.1016/j.intimp.2019.105776 ↗
44. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis – Xenograft model10.1016/j.jaut.2014.07.003 ↗
45. The use of external mesh reinforcement to reduce intimal hyperplasia and preserve the structure of human saphenous veins10.1016/j.biomaterials.2013.12.041 ↗
46. A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study10.1016/j.ijpharm.2012.02.023 ↗
47. Design and characterization of a perivascular PLGA coated PET mesh sustaining the release of atorvastatin for the prevention of intimal hyperplasia10.1016/j.ijpharm.2017.12.026 ↗
48. Perivascular administration of drugs and genes as a means of reducing vein graft failure10.1016/j.coph.2012.02.012 ↗
49. Coating techniques and release kinetics of drug-eluting stents
50. M.R. Bennett, M.O. Sullivan, Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy, 91 (2001) 149–166.10.1016/S0163-7258(01)00153-X ↗
51. S.A. Goel, L.-W. Guo, B. Liu, K.C. Kent, Mechanisms of post-intervention arterial remodelling. https://doi.org/10.1093/cvr/cvs276.10.1093/cvr/cvs276 ↗